 About Entrez
NCBI Toolbar
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My
NCBI
Related
Resources
Order Documents
NLM
Mobile
NLM Catalog
NLM
Gateway
TOXNET
Consumer
Health
Clinical Alerts
ClinicalTrials.gov
PubMed
Central |
|
|
Note: |
|
Performing your original search,
vassilopoulou-sellin, in PubMed will retrieve 113
citations. |
| Display Show |
 |
|
|
-
Estrogen replacement therapy in
women with prior diagnosis and treatment for breast
cancer.
Vassilopoulou-Sellin
R, Theriault
R, Klein
MJ.
Section of Endocrinology, University of Texas M.D.
Anderson Cancer Center, Houston 77030, USA.
We followed 49 women
who underwent a minimum of 2 years estrogen replacement therapy (ERT)
after diagnosis and treatment for localized breast cancer. Forty-three
women were treated with oral ERT. In this group, the median age at the
time of cancer diagnosis was 46 years (range 26 to 66 years), and ERT
was begun a median of 84 months after diagnosis (range 0 to 286 months).
The patients were followed for a median of 144 months after cancer
diagnosis (range 46 to 324 months), and the median duration of ERT was
31 months (range 24 to 142 months). For six women, ERT was administered
as a vaginal cream application. In this group, the median age at time of
cancer diagnosis was 46 years (range 38 to 57 years), and ERT was begun
a median of 49 months after diagnosis (range 24 to 61 months). The
patients were followed for a median of 95 months after cancer diagnosis
(range 72 to 154 months), and the median duration of ERT was 47 months
(range 27 to 80 months). One patient experienced disease recurrence; she
had received surgery for a stage I, estrogen receptor (ER)-positive
lesion. The patient began ERT 30 months after cancer diagnosis and
developed a recurrent ER-negative tumor 56 months after initiation of
ERT. She remained alive without evidence of disease for 10 years since
initial diagnosis of breast cancer. Despite the inherent limitations of
retrospective experiential data and the need for prospective, randomized
trials to assess the safety of ERT, the present observations suggest
that ERT does not appear to have a pronounced adverse effect on cancer
outcome. Nevertheless, until appropriate clinical trials determine that
ERT is safe, caution is needed.
MeSH Terms:
Substances:
PMID: 9103397 [PubMed -
indexed for MEDLINE]
| Display Show |
| |